SMAD3 and neoplasm: Overexpression of nuclear C-terminal phosphorylated SMAD3 (p-SMAD3) in preoperative tumor samples was indicated to identify LARC patients at higher risk for poor response to fluoropyrimidine-based nCRT (Huang et al., 2015).